methyl 1-isopropyl-4-nitro-1H-pyrazole-5-carboxylate | 923283-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 1-isopropyl-4-nitro-1H-pyrazole-5-carboxylate
• 英文别名: 1H-Pyrazole-5-carboxylic acid, 1-(1-methylethyl)-4-nitro-, methyl ester；methyl 4-nitro-2-propan-2-ylpyrazole-3-carboxylate
• CAS: 923283-86-7
• 化学式: C₈H₁₁N₃O₄
• 分子量: 213.193
• InChiKey: ZETGPKPUVRMDBP-UHFFFAOYSA-N

物化性质

• 沸点：
  314.5±22.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 1-isopropyl-4-nitro-1H-pyrazole-5-carboxylate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 以81 %的产率得到methyl 4-amino-1-isopropyl-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINONE COMPOUNDS
  [FR] COMPOSÉS PYRAZOLOPYRIMIDINONE

  摘要：

  本文提供了吡唑吡咯啉酮化合物和含有该化合物的制药组合物。

  公开号：

  WO2022204481A1
• 作为产物：
  描述：

  异丙醇 、 4-硝基-1H-吡唑-3-甲酸甲酯 在 三丁基膦 、 偶氮二甲酸二叔丁酯 作用下， 以 四氢呋喃 为溶剂， 以73%的产率得到methyl 1-isopropyl-4-nitro-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents

  摘要：

  We pursued serine palmitoyltransferase (SPT) inhibitors as novel cancer therapeutic agents based on a correlation between SPT inhibition and growth suppression of cancer cells. High-throughput screening and medicinal chemistry efforts led to the identification of structurally diverse SPT inhibitors 4 and 5. Both compounds potently inhibited SPT enzyme and decreased intracellular ceramide content. In addition, they suppressed cell growth of human lung adenocarcinoma HCC4006 and acute promyelocytic leukemia PL-21, and displayed good pharmacokinetic profiles. Reduction of 3-ketodihydrosphingosine, the direct downstream product of SPT, was confirmed under in vivo settings after oral administration of compounds 4 and 5. Their anti-tumor efficacy was observed in a PL-21 xenograft mouse model. These results suggested that SPT inhibitors might have potential to be effective cancer therapeutics. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2018.04.008

文献信息

• [EN] PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ D'IRAK4 À BASE DE PYRAZOLOPYRIMIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016144846A1

  公开（公告）日：2016-09-15

  The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式(I)的IRAK4的吡唑吡咯啉抑制剂，并提供包含这种抑制剂的组合物，以及用于治疗IRAK4介导或相关疾病或病症的方法。
• Pyrazolo pyrimidines useful as aurora kinase inhibitors
  申请人：Oslob D. Johan

  公开号：US20070027166A1

  公开（公告）日：2007-02-01

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R 2 , R 4 , X 1A , X 2A , X 1B , X 2B , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下结构的化合物：其中A-B一起代表以下结构之一：其中之一是双键，根据价性而定；而R2、R4、X1A、X2A、X1B、X2B、L1、L2、Y和Z如此处所定义，以及其制药组合物，如此处总体描述和所述的亚类，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于例如治疗由Aurora介导的疾病。
• [EN] PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY<br/>[FR] INHIBITEURS À BASE DE PYRROLOPYRIDAZINE D'ACTIVITÉ D'IRAK4
  申请人：MERCK SHARP & DOHME

  公开号：WO2016144847A1

  公开（公告）日：2016-09-15

  The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式(I)的IRAK4的吡咯吡啶嘧啶抑制剂，并提供包含这种抑制剂的组合物，以及用于治疗IRAK4介导的或相关的疾病或症状的方法。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3287441A1

  公开（公告）日：2018-02-28

  The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

  本发明涉及一种化合物，该化合物可用于治疗或预防与 SPT 有关的疾病，包括癌症和与鞘脂蓄积有关的先天性疾病（包括尼曼-皮克病）。
• Pyrrolopyridazine inhibitors of IRAK4 activity
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10040798B2

  公开（公告）日：2018-08-07

  The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式（I）的IRAK4的吡咯哒嗪抑制剂，并提供了包含这种抑制剂的组合物，以及用其治疗IRAK4介导的或相关的病症或疾病的方法。